linjc16/ctgov huggingface dataset:
A Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions

Study Overview
=================
Brief Summary
-----------------
The Dermacorder measures the electric field in the skin. Malignant skin lesions disrupt the skin's normal electric field and this abnormal electric field can be detected by the Dermacorder. Therefore the investigators are testing the hypothesis that the Dermacorder can provide useful data to guide in the diagnosis of skin disease.

Detailed Description
-----------------
The Dermacorder is a non-invasive medical device that scans a probe over the skin about 200 microns away from it and detects the electric field in the skin using capacitative coupling. Measurements of hundreds of malignant melanomas in mice indicated that these lesions generate an electric field that is easily detected. One previous clinical trial at the VA Medical Center in Hampton VA indicated an 80% reliability in predicting malignant lesions by their electric field. We have improved the Dermacorder over the past two years by enhancing its sensitivity and stability and must now determine if these improvements have improved its ability to detect malignant lesions. If the Dermacorder provides a reliable diagnosis of malignant lesions, its use could dramatically reduce the number of biopsies performed and this would significantly improve the quality of life for hundreds of thousands of Americans seeking the advice of dermatologists regarding suspicious lesions each year

Official Title
-----------------
A Phase I Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions

Conditions
-----------------
Basal Cell Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Study subjects must have had diagnosed at least one benign or malignant skin lesion; Subject is from 18-75 years of age, inclusive; Subject must sign and date all informed consent statements. Exclusion Criteria: Subject is exhibiting signs of a bacterial or viral infection, including fever; Subject is unwilling to allow a biopsy of a malignant lesion for histological analysis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dermacorder, Electric field, basal cell carcinoma, Gorlin Syndrome
The Correlation Between B-type Natriuretic Peptide (BNP) and Global End Diastolic Volume

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesized that the serum B-type Natriuretic Peptide (BNP) level may be correlated with global end diastolic volume (GEDV) as measured by transpulmonary thermodilution technique (PiCCO). The rationale is that some animal studies have proven that BNP is released from ventricular myocardium in response to physical expansion. Such physical expansion can be measured by GEDV. If the hypothesis can be confirmed with our study, the serum level BNP can be used to monitor volume status of critically ill patient, instead of the invasive monitoring system.

Official Title
-----------------
The Correlation Between BNP and Global End Diastolic Volume

Conditions
-----------------
Critically Ill

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: critically ill patients who required hemodynamic monitoring using PiCCO Exclusion Criteria: patients with renal dysfunction those older than 80 years pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| consecutive patients<br>there is only one group in our study | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| global end diastolic volume | this is measured by transpulmonary thermodilution technique | within 12 h after measurement of BNP | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
B-type natriuretic peptide, global end diastolic volume
Growth and Tolerance of Infants Fed Formula for 16 Weeks

Study Overview
=================
Brief Summary
-----------------
Growth and Tolerance Trial of Iron-fortified infant formulas

Detailed Description
-----------------
16 WEEK GROWTH AND TOLERANCE

Official Title
-----------------
Growth Monitoring Study of Infants Fed Formula for 16 Weeks

Conditions
-----------------
Child Development

Intervention / Treatment
-----------------
* Other: Infant formula


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy term infants, 37-42 weeks gestational age Exclusion Criteria: Any condition that would negatively impact assessment of growth and tolerance

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 14 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Multi-Investigator, Prospective, Randomized Clinical Trial
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Growth, Tolerance of Infants-Exp<br>Infant Formula | Other: Infant formula<br>* Multi-centered, prospective, randomized clinical trial<br>|
| Active Comparator: Growth,Tolerance of Infants-Com<br>Infant Formula | Other: Infant formula<br>* Multi-centered, prospective, randomized clinical trial<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Growth | Weight Gain | 16 weeks |
Clinical and Biomechanics Research in Core Muscles After Lumbar Fusion Surgery

Study Overview
=================
Brief Summary
-----------------
Lumbar fusion has been widely used for spinal disorders when conservative treatment has failed. However, a number of studies have reported that the rate of re-operation is high for lumbar fusion surgery. Swelling, atrophy or fat infiltration of the paraspinal muscles at the surgery site can cause weakness and pain. After fusion, the range of motion is constrained at the fused spine and might facilitate compensative movement of the adjacent levels and increase degeneration rate of the spine. Evidence has shown that core muscles play an important role to stabilize and support the spine. Whether core stability exercise can enhance spinal stability after lumbar fusion surgery remains unclear. Therefore, the overall goal of this proposed research is to investigate how core muscles affect outcomes after lumbar spinal fusion. The investigators will explore this issue hierarchically and systematically in 3-year duration.

Official Title
-----------------
Clinical and Biomechanics Research in Core Muscles After Lumbar Fusion Surgery

Conditions
-----------------
Lumbar Fusion, Lumbar Spinal Fusion Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ages between 20 and 85 years, back pain and/or sciatica exceeding 12 weeks for which conservative treatment had failed to improve, a primary diagnosis of spinal stenosis, spondylosis, degenerative or isthmic spondylolisthesis or degenerative disc disease, and the patient selected for lumbar surgery Exclusion Criteria: mechanical back pain due to posture changes and cannot maintain an upright posture over 30 minutes; segmental instability that includes isthmic spondylolisthesis, degenerative spondylolisthesis over 0.4 cm; intervertebral angle reversal on dynamic radiographs; and previous lumbar fusion, rheumatoid arthritis, and ankylosing spondylitis.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Lumbar spinal surgery<br>The study included participants who were diagnosed by a neurological surgeon and received lumbar surgery according to relevant imaging findings | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
assessment model, biomechanical changes, functional activities, magnetic resonance imaging (MRI), causal relationship, core muscles activation pattern, pathological changes, early rehabilitation, core stability exercise, minimally invasive lumbar spinal fusion surgery
Outpatient Evaluation of Patients With Known or Suspected Heart Disease

Study Overview
=================
Brief Summary
-----------------
This study is designed to screen patients with heart diseases who may qualify to participate in other research studies being conducted by the Cardiology Branch of the National Heart, Lung, and Blood Institute (NHLBI). Patients participating in this research study will be seen on an outpatient basis and undergo a general medical evaluation, including blood tests, urine, examination, chest x-ray and electrocardiogram (EKG). In addition, patients may be asked to have an echocardiogram (ultrasound scan of the heart) and to perform an exercise stress test. Patients participating in this study will not receive any investigational treatments.

Detailed Description
-----------------
This protocol permits outpatient screening of patients with cardiovascular diseases who may be candidates for participation in current Cardiology Branch research protocols. No investigational treatments will be administered on this protocol.

Official Title
-----------------
Outpatient Evaluation of Patients With Known or Suspected Heart Disease (Screening Protocol)

Conditions
-----------------
Heart Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Must not be enrolled in an active Cardiology Branch research protocol. The patient must be of scientific interest to the Cardiology Branch, as determined by the investigator. Patient is being screened for participation in an active protocol.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Heart Disease, Screening, Follow-Up
Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to demonstrate pharmacodynamic comparability between the pantoprazole spheroid formulation and the marketed tablet formulation.

Official Title
-----------------
A Randomized, 2-Period, Crossover, Pharmacodynamic Comparability Study Comparing A Pantoprazole Spheroid Formulation to the Currently Marketed Tablet Formulation in Subjects With GERD and a History of Erosive Esophagitis.

Conditions
-----------------
Gastroesophageal Reflux, Esophagitis

Intervention / Treatment
-----------------
* Drug: Pantoprazole for approximately 9 weeks


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: GERD and a history of Erosive Esophagitis documented by endoscopy H. pylori negative Exclusion Criteria: Gastrointestinal conditions such as esophageal stricture, esophageal varices, previous vagotomy Achlorhydria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Pantoprazole for approximately 9 weeks|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of MAO between the two formulations. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of BAO and pH parameters between the two formulations. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Gastroesophageal Reflux Disease (GERD)
Simultaneously PET/MRI in Prolonged DOC Patients

Study Overview
=================
Brief Summary
-----------------
Recently introduced hybrid PET/MR scanners provide the opportunity to measure simultaneously, and in direct spatial correspondence, both metabolic demand and functional activity of the brain, hence capturing complementary information on the brain's physiological state. Here we exploited PET/MR simultaneous imaging to explore the relationship between the metabolic information provided by resting-state fluorodeoxyglucose-PET (FDG-PET) and fMRI (rs-fMRI) in patients with disorders of consciousness.

Official Title
-----------------
Relationship Between Simultaneously Acquired Resting-state Regional Cerebral Glucose Metabolism and Functional MRI in DOC: a PET/MR Hybrid Scanner Study

Conditions
-----------------
Disorder of Consciousness, Minimally Conscious State, FDG-PET, Rs-fMRI

Intervention / Treatment
-----------------
* Diagnostic Test: Multimodal Neuroimaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: DOC patients （acute, subacute or chronic period）: Coma, UWS and MCS. Exclusion Criteria: neuromuscular blocking agents or sedative drugs administered within the prior 24 hours； unstable medical condition； mental implant in the brain

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with disorders of consciousness<br> | Diagnostic Test: Multimodal Neuroimaging<br>* fludeoxyglucose (FDG-)PET/MR imaging<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| resting-state fMRI | Use resting-state fMRI to test the functional connectivity | Within 7 days | 
| fludeoxyglucose (FDG-)PET | UseFDG-PET to test the metabolism. | Within 7 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Disorder of Consciousness, Unresponsive wakefulness syndrome, Multimodal Neuroimaging
Nutritional Problems in Pallative Cancer

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to investigate those nutritional problems contributing to loss of lean body mass in lung and pancreas cancer patients in chemotherapy. Furthermore to investigate alterations in taste and how they correlates with changes in following factors: nutritional intake, physical activity, appetite, food preferences, side effects, fatique and meal perception.

Detailed Description
-----------------
This study will include a recruitment of 50 lung and pancreas cancer patients currently in chemotherapy. They will be observed during a period of 9-12 week, including at least 2 chemotherapy treatments. The presence and severity of the nutritional problems will be examined by observing as many different factors as possible. This includes taste alterations, weight changes, nutritional intake, physical activity, interviews and weekly questionnaires. In relation to this our primary outcome is to investigate the correlation between changes in taste and changes in nutritional intake. Secondarily the investigators want to investigate nutritional intake, physical activity, appetite, food preferences, side effects, fatique and meal perception.

Official Title
-----------------
Observational Study of Nutritional Problems in Lung and Pancreas Cancer Patients in Chemotherapy

Conditions
-----------------
Pancreatic Cancer, Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Lung or pancreas cancer patient In chemoterapy regardless of line treatment with/without combined treatment Legal age Able to speak and read in danish Ambulant Exclusion Criteria: Inability to give consent and complete questionnaires Participating in clinical interventions during the periode of observation Allergic to milk or for any reason don't consume diary products

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To investigate the correlation between changes in taste and changes in nutritional intake | Changes in taste measured by a sensory test combined with questionnaires, and changes in nutrional intake is measured by photografies of meals | 9-12 weeks (3 treatment cycles) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Malnutrition, cancer, weight loss, lean body mass
Shifts in the Oral Biofilm of Patients With Known Oral Health Risk Factors

Study Overview
=================
Brief Summary
-----------------
This study is observational only and is intended to evaluate changes in the makeup and function of bacteria naturally present in the mouth during treatment with braces to straighten teeth.

Official Title
-----------------
Shifts in the Oral Biofilm of Patients With Known Oral Health Risk Factors

Conditions
-----------------
Dental Caries, Gingivitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA I or II (ASA I is a healthy patient, ASA II is patient with minor systemic disease) Patient must be receiving orthodontic treatment at the University of North Carolina School of Dentistry and not yet be in active treatment Exclusion Criteria: Patients who have used antibacterial therapy in the past 3 months Patients who report current smoking ASA III or above (Patients with severe systemic diseases)

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Shannon diversity index from Baseline to Month 6 |  | Baseline, Month 6 | 
| Change from Baseline to Month 6 in Clusters Of Orthologous Groups of proteins |  | Baseline, Month 6 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in gingival index |  | Baseline, Month 6 | 
| Change in decalcification index |  | Baseline, Month 6 |
Reducing Asthma Disparities by Improving Provider-Patient Communication

Study Overview
=================
Brief Summary
-----------------
The purpose of this study will be to assess the impact of a culturally-sensitive, patient-focused asthma communication instrument (ACCI) designed to enhance provider-patient communication by prompting and guiding providers in assessments of disease severity and discussion of adherence behaviors with minority patients with asthma.

Detailed Description
-----------------
Improving communication between health care providers and their patients is the critical first step in efforts designed to reduce asthma-related health disparities in urban areas. Improving communication will help providers tailor asthma therapies to their patients' needs, and help providers and patients to overcome barriers (e.g., concerns about adverse effects) to adherence with those asthma treatment plans.

Official Title
-----------------
Reducing Asthma Disparities by Improving Provider-Patient Communication About Asthma Severity and Adherence With Therapy

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Device: Asthma Control and Communication Instrument


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: are able to provide informed consent; report physician-diagnosed asthma; report asthma symptoms and/or use of short-acting reliever medication at least twice weekly in the past month. Exclusion Criteria: state they do not have asthma; have mild intermittent disease no recent evidence of disease activity.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Asthma Control and Communication Instrument|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy of Provider Assessment of Asthma Severity |  |  | 
| Accuracy of Clinician Assessment of Patient Adherence |  |  | 
| Assessment of appropriateness of asthma treatment (consistency of care with asthma guidelines |  |  | 
| Patient satisfaction with provider-patient communication and medical care |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| These outcomes include indicators of poor asthma control such as health care service use for asthma exacerbations (unscheduled office visits, ER visits, hospitalizations) and use of oral corticosteroid and overuse of inhaled beta-agonist medications. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma